Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of monthly subcutaneous fremanezumab in children and adolescents with episodic or chronic migraine
MOH_2020-11-18_009518Phase 3Recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of fremanezumab in migraine and chronic migraine (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Long-term safety and tolerability of subcutaneous fremanezumab. Started Nov 2020; status: recruiting.
02
Drugs
fremanezumab
03
Conditions
migrainechronic migraine
Beyond the preview
Go deeper on MOH_2020-11-18_009518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-11-18_009518.